Status:

COMPLETED

MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Lead Sponsor:

Centre Francois Baclesse

Collaborating Sponsors:

UCOG (Unite de coordination en Onco-Gériatrie)

Conditions:

Neoplasms

Eligibility:

All Genders

70+ years

Phase:

NA

Brief Summary

This study concerns elderly patients with cancer with onco-geriatric assessment. This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the ...

Eligibility Criteria

Inclusion

  • Patient aged over 70 years
  • Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.
  • Patient candidate for oncogeriatric assessment
  • Patient agree to participate in the study
  • Using the French language

Exclusion

  • Primary central nervous system or cerebral metastasis
  • Evolutionary psychiatric pathology known (e.g. schizophrenia)
  • Severe Visual and / or Auditory Impairment
  • Patients unable to respond to cognitive tests
  • Patient (s) deprived of liberty, under guardianship or curatorship
  • Refusal of participation

Key Trial Info

Start Date :

October 13 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 13 2023

Estimated Enrollment :

104 Patients enrolled

Trial Details

Trial ID

NCT03299855

Start Date

October 13 2017

End Date

October 13 2023

Last Update

October 18 2023

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Centre François Baclesse

Caen, France

2

CHU

Caen, France

3

CH

Cherbourg, France

4

Ch Compiegne

Compiègne, France

MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric? | DecenTrialz